Stay updated on Surufatinib in Biliary Tract Carcinoma: Clinical Trial
Sign up to get notified when there's something new on the Surufatinib in Biliary Tract Carcinoma: Clinical Trial page.

Latest updates to the Surufatinib in Biliary Tract Carcinoma: Clinical Trial page
- Check7 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest has been deleted.SummaryDifference0.9%
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.7%
- Check28 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check43 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, and API users can provide input before this change. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check71 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check85 days agoChange DetectedThe page has undergone significant changes, including the removal of detailed descriptions of a clinical study on surufatinib versus Capecitabine for biliary tract cancer, and the addition of a new version revision number. The study's inclusion and exclusion criteria have also been altered, impacting the understanding of the study's parameters.SummaryDifference52%
Stay in the know with updates to Surufatinib in Biliary Tract Carcinoma: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Surufatinib in Biliary Tract Carcinoma: Clinical Trial page.